First human trial tests engineered immune cells against tough cancers
NCT ID NCT07231081
Summary
This early-stage study is testing a new type of cancer treatment called TX103 CAR-T cell therapy in adults with advanced solid tumors that have a specific protein marker. The main goals are to check if the treatment is safe, find the right dose, and see if it shows any signs of fighting the cancer. The study will enroll about 85 people whose cancers have progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
NOT_YET_RECRUITINGBeijing, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Gaobo Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.